EP2059206A2 - Pansement de plaie sec et système de délivrance de médicament - Google Patents

Pansement de plaie sec et système de délivrance de médicament

Info

Publication number
EP2059206A2
EP2059206A2 EP07841486A EP07841486A EP2059206A2 EP 2059206 A2 EP2059206 A2 EP 2059206A2 EP 07841486 A EP07841486 A EP 07841486A EP 07841486 A EP07841486 A EP 07841486A EP 2059206 A2 EP2059206 A2 EP 2059206A2
Authority
EP
European Patent Office
Prior art keywords
weight
composition
polyvinylpyrrolidone
ulcers
fibronectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP07841486A
Other languages
German (de)
English (en)
Other versions
EP2059206B1 (fr
EP2059206A4 (fr
EP2059206B8 (fr
Inventor
Clyde Raymond Goodheart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
REXADERM Inc
Original Assignee
REXADERM Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by REXADERM Inc filed Critical REXADERM Inc
Priority to EP12167927.8A priority Critical patent/EP2489338B1/fr
Publication of EP2059206A2 publication Critical patent/EP2059206A2/fr
Publication of EP2059206A4 publication Critical patent/EP2059206A4/fr
Publication of EP2059206B1 publication Critical patent/EP2059206B1/fr
Application granted granted Critical
Publication of EP2059206B8 publication Critical patent/EP2059206B8/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/225—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/425—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Dry dressings incorporate drug-delivery systems for anti-infective agents, growth factors, fibronectin or other substances to enhance tissue healing.
  • Certain types of wounds are difficult to heal, e.g., diabetic leg and foot ulcers, venous stasis ulcers, decubitus ulcers, and severe burns.
  • Dressings incorporating agents to assist healing such as fibronectins, or to control infection, such as antibiotics and antimicrobials, are an approach for use on difficult to heal wounds.
  • storage of these "wet dressings” generally requires preservative agents, which are not optimal to place on wounds.
  • a pharmaceutical composition includes hyaluronate, polyvinylpyrrolidone
  • PVP polyvinyl cellulose
  • hydroxyethylcellulose hydroxyethylcellulose
  • glycerin in the form of a membranous, wafer-like material after being lyophilized (freeze-dried).
  • ingredients optionally include human cellular fibronectin (cFN), growth factors, antimicrobial agents, and a buffering system.
  • cFN human cellular fibronectin
  • a dry wound dressing including the pharmaceutical composition is useful for treatment of abrasions, ulcers, burns, traumatic and surgical wounds.
  • the dressing may be in the form of an adhesive strip.
  • the dressing is useful to cover oral sores, mucositis or stomatitis resulting from chemotherapy, radiation therapy, dental braces, aphthous ulcers, or stem cell therapy, for chronic ulcers, such as diabetic ulcers, decubitus ulcers, and venous stasis ulcers.
  • a method to deliver agents such as fibronectin to a wound includes the steps of:
  • a suitable composition is made, before lyophilization, from about 0.04% to about 15% by weight/volume of hyaluronic acid, or a pharmaceutically acceptable salt thereof, having a molecular weight from about 500,000 daltons to about 2.2 million daltons; from about 1% to about 5% by weight/volume of a K60 to KlOO polyvinylpyrrolidone.
  • ingredients optionally include an antibacterial agent, disinfectant agent, antifungal agent, antiviral agent, analgesic, anti-inflammatory, emollient, or a local anesthetic.
  • a composition used for treating or preventing inflammation in a patient includes administering to a patient in need thereof an effective amount of a composition made, before lyophilization, (i) from about 0.01 to about 5 percent by weight of hyaluronic acid, or a pharmaceutically acceptable salt thereof, having a molecular weight from about 500,000 to about 2.2 million daltons; (ii) from about 0.04% to about 15% by weight/volume of a K60 to KlOO polyvinylpyrrolidone; and (iii) from about 86 to about 98% water.
  • a composition used for treating or preventing inflammation in the oral cavity of a patient includes administering to the oral cavity of a patient in need thereof an effective amount of a composition comprising, before lyophilization, (i) from about 0.01 to about 5 percent by weight of hyaluronic acid, or a pharmaceutically acceptable salt thereof, having a molecular weight from about 500,000 daltons to about 2.2 million daltons; (ii) from about 0.04 to about 15% by weight of a K60 to KlOO polyvinylpyrrolidone;
  • a composition used for treating or preventing mucositis in a patient includes an effective amount of a composition comprising, before lyophilization, (i) from about 0.01 to about 5 percent by weight of hyaluronic acid, or a pharmaceutically acceptable salt thereof, having a molecular weight from about 500,000 daltons to about 2.2 million daltons; (ii) from about 0.04 to about 15% by weight of a K60 to KlOO polyvinylpyrrolidone;
  • a composition used for treating pain resulting from oral surgery in a patient includes an effective amount of a composition comprising, before lyophilization, (i) from about 0.01 to about 5 percent by weight of hyaluronic acid, or a pharmaceutically acceptable salt thereof, having a molecular weight from about 500,000 daltons to about 2.2 million daltons; (ii) from about 0.04 to about 15% by weight of a K60 to KlOO polyvinylpyrrolidone.
  • FIG. 1-6 are a series of 6 pictures taken sequentially after treatment of a leg ulcer, which had persisted for over 6 months without healing, using the dry dressing described herein that contained human cellular fibronectin (cFN).
  • FIG. 1 is the appearance of the lesion (about 12-15 mm) after the wound was treated with Bactroban for two weeks. .
  • FIG. 2 was taken after two treatments of 48 hours each with the dry dressing.
  • FIG. 3 shows the cFN dressing applied to the wound.
  • FIG. 4 was taken after ten days of treatment, picture FIG. 5 after two weeks, and picture FIG. 6 after approximately one month.
  • the cFN dressing was held on with either a 4 x 4 sponge and tape or with a BAND-AIDTM (adhesive bandage).
  • BAND-AIDTM asdhesive bandage
  • compositions described herein include the sodium salt of hyaluronic acid (also known as sodium hyaluronate or hyaluronan), polyvinylpyrrolidone (PVP), hydroxyethylcellulose, maltodextrin, glycerin and a buffering system, to which various other substances and medications may be added depending on the intended use of the composition.
  • hyaluronic acid also known as sodium hyaluronate or hyaluronan
  • PVP polyvinylpyrrolidone
  • hydroxyethylcellulose hydroxyethylcellulose
  • maltodextrin glycerin
  • glycerin glycerin
  • buffering system a suitable flavoring and sweetener may be added to enhance the taste.
  • preservatives are not required, because the composition is lyophilized.
  • the ingredients of the compositions have been approved by the U.S. Food and Drug Administration (FDA) for use in foods or in other pharmaceutical uses
  • compositions provide dry wound dressings, drug delivery systems to administer medications or other substances to aid in wound healing, or to administer medications to limited areas of the body.
  • the compositions, into which additional material is mixed before lyophilization to form a membrane or wafer- like material may be prepared in a variety of thicknesses with a specific thickness appropriate for a given intended use. The thickness may be from less than a millimeter to a centimeter, with the preferred thickness for most purposes about 2 millimeters.
  • the formulation may also be made in specific configurations, by freezing it in a mold of the appropriate shape and size before lyophilization.
  • it can be made in the form of a plug to fit into a tooth socket following extraction, or into a curved piece in the shape of a fingernail or toenail, to be applied to a nail bed after avulsion of the nail.
  • the wafer-like material is easily ground into a powder, which powder can be sprinkled over the area to be treated, or it can be mixed with water or other liquid to reconstitute it into a paste-like material for application to the wound.
  • a carrier material for applying fibronectin to wounds was sought to make use of the well-known effectiveness of fibronectin in wound healing.
  • Fibronectin is known to be unstable in solution, but it is stable for years in the lyophilized state, and it is difficult to incorporate it in a liquid or gel. Therefore, a dressing or carrier was sought that could contain fibronectin and that could be lyophilized.
  • the composition described herein accomplished the goal of providing such a carrier. Surprisingly, it was also found that the composition described could be used as a wound dressing and as a carrier or drug delivery system for a number of other pharmaceutical materials that are also involved in various ways in wound treatment.
  • a pharmaceutical composition is described that can be used without further ingredients ("basic”), or it may include one or more of the additional ingredients listed herein.
  • the basic pharmaceutical composition is prepared by dissolving in purified water, all at room temperature with continuous mixing, the following: hyaluronic acid or a pharmaceutically acceptable salt thereof, preferably the sodium salt (also known as hyaluronan), with a molecular weight greater than 500,000 daltons, preferably of 2.2 million daltons or more (which can be obtained from Lifecore Biomedical, Inc., Chaska, Minnesota, among other suppliers) from 0.01% to 5.0% w/v; Maltodextrin (Aldrich Chemical catalog number 419672, dextrose equivalent 4.0 - 7.0) 0.5% to 5% w/v; PVP (polyvinylpyrrolidone) (Fluka Chemical catalog number 81440; molecular weight about 360,000 daltons, 0.04% to 15% w/v; and hydroxyethylcellulose (Spect
  • a pharmaceutical composition consists essentially of the following ingredients: 0.01 to about 5 percent by weight of hyaluronic acid, or a pharmaceutically acceptable salt thereof, having a molecular weight from about 500,000 to about 2.2 million daltons; (ii) from about 0.04 to about 15% by weight of a K60 to KlOO polyvinylpyrrolidone.
  • a buffer system is desirable for most purposes.
  • a pH of about 7.4 (6.8 to 7.8) can be achieved with a phosphate buffer, preferably of 10 mM strength (5 mM to 50 mM), with 0.0312 % w/v monosodium phosphate monohydrate and 0.2075 % w/v disodium phosphate heptahydrate.
  • Formulas for calculating phosphate buffers of other strengths and other pH values are readily available.
  • a similar pH would be appropriate for matrix formulations to be used in the eye, in which tears have a pH of about 7.4 to 7.5.
  • Other buffer systems including organic buffers, may be used instead of the citrate and phosphate systems.
  • the pH of the matrix is approximately the same as that of the skin, which in humans is about pH 5.5.
  • a citrate buffer preferably of 10 mM strength (5 mM to 50 mM) can be used to obtain this pH, consisting of 0.0506 % w/v anhydrous citric acid and 0.2233 % w/v sodium citrate dihydrate.
  • Formulas for calculating citrate buffers of other strengths and other pH values are readily available.
  • the mixture is spread in a suitable flat- bottomed container to a depth of about 2 mm, and frozen.
  • the depth of the mixture may be increased or decreased, if desired, to form a wafer of greater or lesser thickness, depending on the proposed use.
  • polystrene is preferred, as it has been found that the matrix releases more readily from that surface than from other plastics or from glass.
  • the containers of frozen mixture are then placed in a lyophilizer and dried directly from the frozen state.
  • the resulting material after lyophilization is a light, fluffy, white membrane or wafer-like material, much like blotting paper.
  • the membrane may be compressed by rolling to form a thinner, but tougher membrane.
  • compositions or dressings When the composition is placed on a wound, it quickly absorbs moisture and adheres tightly to the surface, forming a protective covering. Although the dressing is adherent after it absorbs moisture, optionally it may be covered with tape or held in place with gauze or an elastic bandage. Antibiotics or other active pharmaceutical ingredients incorporated in the material are released into the wound.
  • the pharmaceutical compositions or dressings may be sterile, e.g., by using filtered ingredients and by aseptic handling.
  • the membrane or wafer is placed in the mouth and allowed to dissolve and coat the afflicted area.
  • the formulation may also be used in a liquid form, by mixing the dried material (wafer- like or powder) with water, and used to treat pharyngitis, esophagitis, and gastritis, and can be administered rectally to treat proctitis, colitis, and similar conditions.
  • the wafer-like membrane, in which soothing medications, including hydrocortisone, were incorporated, can be applied externally to hemorrhoids.
  • the compositions may be used post-operatively (e.g., bowel resection, explorations and the like) to decrease risk of adhesions, decrease risk of infections, improve surgical healing, and gain other therapeutic effects, such as its anti-inflammatory action.
  • Ophthalmic uses include treating conjunctivitis and keratitis, and postoperatively for any procedures involving the anterior and, possibly, posterior eye, either as firm or liquid dressings.
  • placement of a small piece of appropriately shaped membrane into the conjunctival sac allows drug delivery for 12 to 24 hours as well as adding "softness" to the natural lacrimation. This is also suitable for treating keratoconjunctivitis sicca (Sjogren's syndrome).
  • Cellular fibronectin (cFN) may be incorporated in the material placed in the eye for treating nonhealing corneal ulcers.
  • the formulation may be used in the bladder or urethra, as a liquid dressing, or as a lavage solution.
  • the wafer-like material can be used to maintain the integrity of the denuded nail bed.
  • the biomaterial dressing is wetted about every 6 hours to provide a moist chamber for the nail bed and serve as drug delivery vehicle, for antibiotics or for cFN to protect the nail bed and assist in its healing.
  • the membrane or wafer-like material is placed over the area to be treated.
  • the wounds may be those formed in the course of surgical procedures, including the wounds caused by removal of a nevus or skin cancer, the wounds resulting from Mohs surgical procedures, and wounds resulting from removal of skin for transplant.
  • the wafer may have cFN and/or one or more growth factor(s), such as epidermal growth factor, incorporated in it.
  • Saline or water can be used to moisten the area before placing the membrane if there is insufficient moisture from the wound.
  • the wafer may be made adherent to an adhesive strip, as in a Band- AidTM, which will hold it to the wound. In this way, the composition can deliver to the wound, agents to combat infection, and other substances to enhance healing, such as cFN.
  • the membrane or wafer-like material, to which cFN has been added may be used to coat cut surfaces of tissues following surgery for cancers, such as breast cancer, to help decrease the incidence of local recurrence of the cancer, as described in Murthy et al. (1993), and in US Patent #5,354,269.
  • compositions can be incorporated in the mixture before lyophilization to enhance the healing properties of the membrane; the specific medication or substance to be added depends on the use for that particular product.
  • the membrane can be used without additional materials.
  • Materials or medications to be incorporated in the membrane include, as examples, various antibiotics, anti-infectives, and antimicrobials, such as neomycin sulfate, penicillin, streptomycin; silver, sulfadiazine, or cerium nitrate; fibronectin; growth factors, such as epidermal growth factor, keratinocyte growth factor or fibroblast growth factor; topical anesthetic agents; hormones; chemotherapeutics, such as bleomycin or 5-fluorouracil (5-FU); or mixtures thereof.
  • a list of potential applications of the compositions are in Table 1, which is intended only as examples, and it is not intended to limit the composition to those examples.
  • a sample of the basic material was prepared as follows. Fifty mL of distilled water was placed in a 250 mL beaker equipped with a stir bar, on a magnetic stirring apparatus. Maltodextrin (Aldrich 419672; Lot 10910PD; Dextrose equivalent 4.0 - 7.0) 1.25, was added which dissolved quickly. Add PVP (polyvinlypyrrholidon) (Fluka 81440; Lot 1195730 51006177; MW -360,000) 1.80 g, which required about 45 minutes to dissolve. Add hydroxyethylcellulose (Spectrum Chemicals H 1236; Lot VO0782; 5,000 cps) 0.30 g, which dissolved quickly, with stirring.
  • PVP polyvinlypyrrholidon
  • Example 1 (U.S. Pat. No. 5,750,378) using 1.5 mL distilled water. Then 4.5 mL of the concentrated mixture described in Example 1 was mixed into the fibronectin solution. The whole was spread in the bottom of a flat-bottomed plastic container, frozen, and lyophilized along with the samples in Example 1. This preparation resembled the compositions without the fibronectin, except that it appeared to be less friable.
  • EXAMPLE 3 Dry Wound Dressings of Examples 1 and 2 on a Leg Wound [00037] This is a case report of a 72-year old white man who had a diabetic leg ulcer that had persisted about one year. A few months after the lesion occurred, a dermatologist obtained a biopsy sample, and the ulcer became infected, resulting in a larger lesion that was greatly inflamed. The lesion was treated with AveloxTM. It appeared to heal in a few months, when the patient removed what appeared to be dead skin. The lesion opened again, and the patient treated it with Neosporin, Iodine, and Merthiolate. The dermatologist took a swab of the lesion.
  • FIGS. 1-6 Pictures of the lesion along the way at each change are shown in FIGS. 1-6.
  • EXAMPLE 4 Evaluation of Antimicrobial Activity 8] The in vitro antimicrobial activity of the composition was tested using the standard Kirby-Bauer method. Samples designated “Base” were the basic matrix material without added antimicrobials. The sample designated “Base + Silver” additionally contained silver sulfadiazine at pre-lyophilization concentration of 1% w/v. The sample designated “Base + Cerium” contained additionally cerium nitrate at a pre-lyophilization concentration of 0.4% w/v, and the sample designated "Base + Silver + Cerium” additionally contained both compounds at the above concentrations.
  • cFN human cellular fibronectin
  • Human foreskin fibroblasts were obtained from Cambrex Bioscience (now part of Lonza Group, Ltd., Basel, Switzerland) and were grown to confluency in medium MCDB 105 (Sigma Chemical) supplemented with 5% fetal bovine serum; other fibroblast growth medium could also be used.
  • the first addition of production medium was discarded from the roller bottles after two days, and was replaced with fresh production medium (100 mL/bottle). This conditioned medium was harvested every 3 to 4 days and replaced with fresh production medium. After harvesting, the conditioned medium was filtered through a fiberglass filter to remove any cells or cell debris, and was pumped through a gelatin- sepharose (GE Healthcare, Uppsala, Sweden) column. After rinsing the column bed with a dilute phosphate buffer to remove unattached proteins, the adherent fibronectin was eluted with CAPS buffer (Sigma Chemical) at pH 11.0 containing urea (American Bioanalytical) 4 mol/L.
  • CAPS buffer Sigma Chemical
  • the peak fractions determined by spectrophotometry at 280 nm, were pooled and further purified by passing through a Sephedex G-25 (Sigma Chemical) column to removed urea and salts, and to change the buffer to a dilute phosphate buffer.
  • the peak fractions were pooled, and concentrated buffer added so that the final buffer would be physiologic after lyophilization.
  • the solution was sterilized by passing through a sterile 0.22 ⁇ m filter, and was dispensed into sterile vials in a volume containing 1 mg of fibronectin per vial. The vials were frozen and lyophilized.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des pansements secs qui incorporent des systèmes de délivrance de médicament pour des agents anti-infectieux, des facteurs de croissance, la fibronectine ou d'autres substances pour améliorer la cicatrisation des tissus. Une composition pharmaceutique comprend du hyaluronate, de la polyvinylpyrrolidone (PVP), de la maltodextrine, de l'hydroxyéthylcellulose et de la glycérine sous la forme d'un matériau membranaire, de type plaquette après avoir été lyophilisé.
EP07841486A 2006-08-28 2007-08-28 Pansement de plaie sec et système de délivrance de médicament Not-in-force EP2059206B8 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12167927.8A EP2489338B1 (fr) 2006-08-28 2007-08-28 Pansement de plaie sec et système de délivrance de médicament

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84026506P 2006-08-28 2006-08-28
PCT/US2007/077014 WO2008027904A2 (fr) 2006-08-28 2007-08-28 Pansement de plaie sec et système de délivrance de médicament

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP12167927.8A Division EP2489338B1 (fr) 2006-08-28 2007-08-28 Pansement de plaie sec et système de délivrance de médicament
EP12167927.8 Division-Into 2012-05-14

Publications (4)

Publication Number Publication Date
EP2059206A2 true EP2059206A2 (fr) 2009-05-20
EP2059206A4 EP2059206A4 (fr) 2010-12-01
EP2059206B1 EP2059206B1 (fr) 2012-05-16
EP2059206B8 EP2059206B8 (fr) 2012-07-11

Family

ID=39136800

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07841486A Not-in-force EP2059206B8 (fr) 2006-08-28 2007-08-28 Pansement de plaie sec et système de délivrance de médicament
EP12167927.8A Not-in-force EP2489338B1 (fr) 2006-08-28 2007-08-28 Pansement de plaie sec et système de délivrance de médicament

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP12167927.8A Not-in-force EP2489338B1 (fr) 2006-08-28 2007-08-28 Pansement de plaie sec et système de délivrance de médicament

Country Status (4)

Country Link
US (1) US8377468B2 (fr)
EP (2) EP2059206B8 (fr)
BR (1) BRPI0716270A2 (fr)
WO (1) WO2008027904A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030643A1 (it) 2003-04-01 2004-10-02 Copan Innovation Ltd Tampone per il prelievo di campioni biologici
WO2010125069A1 (fr) * 2009-04-28 2010-11-04 Pharmasurgics In Sweden Ab Acide hyaluronique utilisé pour prévenir les adhésions après intervention chirurgicale
IT1396935B1 (it) * 2009-11-26 2012-12-20 Solartium Entpr Ltd Uso di una combinazione per il trattamento delle mucositi indotte da radiazioni o da chemioterapici
IT1401447B1 (it) * 2010-06-09 2013-07-26 Copan Italia Spa Metodo per il trasferimento quantitativo di analiti
IT1403618B1 (it) 2011-01-05 2013-10-31 Copan Italia Spa Procedimento per realizzare un dispositivo per il prelievo ed il trasferimento di campioni per biologia molecolare
JP6357228B2 (ja) 2013-07-10 2018-07-11 マトリックス バイオロジー インスティテュート 高い弾性を有するヒアルロナンの組成物およびその使用
WO2015073919A1 (fr) * 2013-11-14 2015-05-21 University Medical Pharmaceuticals Corporation Micro-aiguilles pour l'administration d'un agent thérapeutique avec des propriétés mécaniques améliorées
EP3056195A1 (fr) * 2015-02-13 2016-08-17 Vision:Organic GmbH Compositions contenant de l'acide hyaluronique et du bêta-glucane pour des applications topiques dans une cavité orale
WO2017053339A1 (fr) * 2015-09-24 2017-03-30 Matrix Biology Institute Compositions d'hyaluronane à haute élasticité et leurs procédés d'utilisation
RU2620019C2 (ru) * 2015-10-05 2017-05-22 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы Способ коррекции пролежней у спинальных больных
EP3492073B1 (fr) * 2016-07-27 2022-04-27 Ritapharma, Co., Ltd. Matériau d'application pour la muqueuse buccale et son procédé de production.
US10952959B2 (en) * 2017-01-11 2021-03-23 Ferring B.V. Fast disintegrating pharmaceutical composition
RU2649785C1 (ru) * 2017-02-22 2018-04-04 Светлана Константиновна Матело Антисептическая композиция, содержащая поливинилпирролидон и унитиол, применение такой композиции и способ обработки ран с ее использованием
CN115177782B (zh) * 2021-04-02 2023-07-18 诺一迈尔(山东)医学科技有限公司 一种高透气、促愈合的液体创可贴及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526865A1 (fr) * 1991-08-05 1993-02-10 FIDIA S.p.A. Matériaux spongieux se composant essentiellement d'acide hyaluronique ou de ses dérivés et son utilisation dans la microchirurgie
WO2002009637A2 (fr) * 2000-07-28 2002-02-07 Sinclair Pharmaceuticals Limited Compositions pharmaceutiques permettant le traitement d'etats pathologiques douloureux, inflammatoires et ulcereux de surfaces epitheliales humides, tels que la mucosite, la stomatite et le syndrome de behcet
US20040254143A1 (en) * 2000-07-28 2004-12-16 Sinclair Pharmaceuticals, Ltd. Compositions and methods for the treatment or prevention of inflammation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2693438A (en) * 1951-02-21 1954-11-02 Norwich Pharma Co Preformed, nonadherent films for application to open lesions
US5124155A (en) * 1988-06-21 1992-06-23 Chiron Ophthalmics, Inc. Fibronectin wound-healing dressings
US5804213A (en) * 1991-10-09 1998-09-08 Lectec Corporation Biologically active aqueous gel wound dressing
US5354269A (en) 1991-12-20 1994-10-11 Fibrogenex, Inc. Method for treating cancer resections
US5750378A (en) 1991-12-20 1998-05-12 Fibrogenex, Inc. Method for preparing cellular fibronectin
GB2368523B (en) * 1999-08-20 2004-05-12 Andre Beaulieu Solid wound healing formulations containing fibronectin
JP3911971B2 (ja) * 1999-09-08 2007-05-09 松下電器産業株式会社 シリコン薄膜、薄膜トランジスタおよびシリコン薄膜の製造方法
US20020122771A1 (en) * 2000-09-23 2002-09-05 Troy Holland Spray hydrogel wound dressings
US6458380B1 (en) * 2000-11-09 2002-10-01 Richard Leaderman Dressing and preparation delivery system
US6635272B2 (en) * 2000-11-09 2003-10-21 Richard N. Leaderman Wound dressing and drug delivery system
AU2003256284A1 (en) * 2002-06-20 2004-01-06 Orapharma, Inc. Rapidly disintegrating formulations for treating or preventing mucositis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526865A1 (fr) * 1991-08-05 1993-02-10 FIDIA S.p.A. Matériaux spongieux se composant essentiellement d'acide hyaluronique ou de ses dérivés et son utilisation dans la microchirurgie
WO2002009637A2 (fr) * 2000-07-28 2002-02-07 Sinclair Pharmaceuticals Limited Compositions pharmaceutiques permettant le traitement d'etats pathologiques douloureux, inflammatoires et ulcereux de surfaces epitheliales humides, tels que la mucosite, la stomatite et le syndrome de behcet
US20040254143A1 (en) * 2000-07-28 2004-12-16 Sinclair Pharmaceuticals, Ltd. Compositions and methods for the treatment or prevention of inflammation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HITA-IGLESIAS ET AL: "Evaluation of the clinical behaviour of a polyvinylpyrrolidone and sodium hyalonurate gel (Gelclair<(>R)) in patients subjected to surgical treatment with CO2 laser" INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, COPENHAGEN, DK, vol. 35, no. 6, 1 June 2006 (2006-06-01), pages 514-517, XP005437546 ISSN: 0901-5027 *
See also references of WO2008027904A2 *
WRIGHT J ET AL: "CHEMOTHERAPY-INDUCED ORAL MUCOSITIS: NEW APPROACHES TO PREVENTION AND MANAGEMENT" EXPERT OPINION ON DRUG SAFETY, ASHLEY, LONDON, GB LNKD- DOI:10.1517/14740338.4.2.193, vol. 4, no. 2, 1 January 2005 (2005-01-01) , pages 193-200, XP009055602 ISSN: 1474-0338 *

Also Published As

Publication number Publication date
EP2059206B1 (fr) 2012-05-16
BRPI0716270A2 (pt) 2013-08-13
WO2008027904A3 (fr) 2008-09-04
EP2059206A4 (fr) 2010-12-01
US8377468B2 (en) 2013-02-19
EP2489338B1 (fr) 2014-05-14
EP2059206B8 (fr) 2012-07-11
US20090325861A1 (en) 2009-12-31
EP2489338A1 (fr) 2012-08-22
WO2008027904A2 (fr) 2008-03-06

Similar Documents

Publication Publication Date Title
EP2059206B1 (fr) Pansement de plaie sec et système de délivrance de médicament
Boateng et al. Wound healing dressings and drug delivery systems: a review
ES2359830T3 (es) Espuma hemostática a base de colágeno.
JP2611159B2 (ja) ヒアルロン酸薬理活性画分、その製造方法および医薬組成物
ES2416458T3 (es) Materiales para vendajes
US9101586B2 (en) Topical application and formulation of erythropoietin for skin wound healing
EP2292257A2 (fr) Compositions et methodes de cicatrisation pour lesions dermatologiques
Khorasani et al. The effects of Aloe Vera cream on split-thickness skin graft donor site management: a randomized, blinded, placebo-controlled study
US20130171093A1 (en) Healing powder and method of use thereof
JPH05506861A (ja) 損傷されたかまたは病気になった組織の局所的処置用の組成物および方法
US20050187185A1 (en) Pharmaceutical applications of hyaluronic acid preparations
JPH10175857A (ja) 創傷治療剤
WO2017060821A1 (fr) Composition hémostatique
CN113855849A (zh) 一种敷料组合物及其制备方法和应用
MXPA03006465A (es) Promocion de la reconstruccion celular y/o diferenciacion celular utilizando azucar no metabolizable y un absorbente polimerico.
US20220249550A1 (en) Preparation and use of tissue matrix derived powder
Khandelwal et al. A comparative study of the effect on healing of ulcer using silver dressing
RU2193896C2 (ru) Покрытие для ран
RU2153352C1 (ru) Фармацевтическая композиция, обладающая ранозаживляющим и противовоспалительным действием
WO2022125593A2 (fr) Compositions et méthodes de traitement de plaies
CN113855850A (zh) 一种敷料组合物及其制备方法和应用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090325

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20101102

RIC1 Information provided on ipc code assigned before grant

Ipc: A61F 13/00 20060101AFI20090326BHEP

Ipc: A61L 15/12 20060101ALI20101026BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/19 20060101ALI20111123BHEP

Ipc: A61F 13/00 20060101AFI20111123BHEP

Ipc: A61L 15/12 20060101ALI20111123BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GOODHEART, CLYDE RAYMOND

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: REXADERM, INC.

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 557684

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120615

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: REXADERM, INC.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007022759

Country of ref document: DE

Effective date: 20120719

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWALT MATTHIAS W. SCHAEFER

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20120516

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

Effective date: 20120516

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120516

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120516

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120916

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120516

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120516

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120516

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 557684

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120516

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120516

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120917

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120817

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120516

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120516

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120516

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120516

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120516

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120516

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120516

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120516

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120516

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120831

26N No opposition filed

Effective date: 20130219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120827

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007022759

Country of ref document: DE

Effective date: 20130219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120828

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120816

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120516

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120516

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070828

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20140827

Year of fee payment: 8

Ref country code: DE

Payment date: 20140827

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20140818

Year of fee payment: 8

Ref country code: GB

Payment date: 20140827

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20140822

Year of fee payment: 8

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007022759

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20150828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150831

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150831

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150828

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20160429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150828

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150831